Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukemia

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 4, 2003, Pages 653-670

  Lo Coco, Francesco ^a   Breccia, Massimo ^b   Noguera, Nélida ^c   Miller Jr , Wilson H ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Acute leukaemia; Chromosome translocations; Fusion genes

Indexed keywords

HYBRID PROTEIN;

ACUTE LEUKEMIA; ARTICLE; CANCER CLASSIFICATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENE IDENTIFICATION; GENETIC DISORDER; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; METAPHASE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; TREATMENT PLANNING; CHROMOSOME ABERRATION; GENE MUTATION; REVIEW;

EID: 0242437941     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00072-0     Document Type: Article

References (76)

1. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Seminars in Hematology 2002; 39: 6-11.
2. Tam W & Dalla-Favera R. Protooncogenes and tumor suppressor genes in hematopoietic malingnancies. In Knowles DM (ed.) Neoplastic Hematology. Philadelphia: Lippincott, Williams & Wilkins 2001, pp 329-363.
3. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
4. Alcalay M, Orleth A, Sebastiani C et al. Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 2001; 20: 5680-5694.
5. Pui CH & Evans WE. Acute lymphoblastic leukaemia. New England Journal of Medicine 1998; 339: 605-615.
6. Lowenberg B, Downing JR & Burnett A. Acute myeloid leukaemia. New England Journal of Medicine 1999; 341: 1051-1062.
7. Burnett AK. Tailoring the treatment of acute myeloid leukaemia. Current Opinion in Hematology 1999; 6: 247-252.
8. Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12-22.
9. Tkachuk DC, Kohler S & Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691-700.
10. Cimino G, Rapanotti MC, Sprovieri T et al. ALL1 gene alterations in acute leukemia: biological and clinical aspects. Haematologica 1998; 83: 350-357.
11. Rubnitz JE, Behm FG & Downing JR. 11q23 rearrangements in acute leukemia. Leukemia 1996; 10: 74-82.
12. Armstrong S, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 2002; 30: 41-47.
13. Friedman AD. Leukemogenesis by CBF oncoproteins. Leukemia 1999; 13: 1932-1942.
14. Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukemia: biology and clinical significance. British Journal of Haematology 1999; 106: 296-308.
15. Speck NA, Stacy T, Wang Q et al. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Research 1999; 59: 1789-1793.
16. Hart SM & Foroni L. Core binding factor genes and human leukemia. Haematologica 2002; 87: 1307-1323.
17. Ferrara F & Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica 2002; 87: 306-319.
18. Delaunay J, Vey N, Leblanc T et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML intergroup. Blood 2003; 120: 462-469.
19. Rubnitz JE, Downing JR & Pui CH. Significance of the TEL-AML fusion gene in childhood AML. Leukemia 1999; 13: 1470-1471.
20. Loh ML & Rubnitz JE. TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Current Opinion in Hematology 2002; 9: 345-352.
21. Nucifora G. The EVII gene in myeloid leucemia. Leukemia 1997; 111: 2022-2031.
22. Jolkowska J & Witt M. The Evi-I gene its role in pathogenesis of human leukemias. Leukemia Research 2000; 24: 553-558.
23. Testoni N, Borsaru G. Martinelli G et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. Haematologica 1999; 84: 690-694.
24. Chen S-J, Wang Z-Y & Chen Z. Acute promyelocytic leukaemia: from clinic to molecular biology. Stem Cells 1995; 13: 22-31.
25. Fenaux P, Chomienne C & Degos L. Acute promyelocytic leukaemia: biology. and treatment. Seminars in Oncology 1997; 24: 92-102.
26. Mann KK, Shao W & Miller Jr WH. The biology of acute promyelocytic leukemia. Current Oncology Reports 2001; 3: 209-216.
27. Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology 1999; 106: 591-613.
28. Arnould C, Philippe C, Bourdon V et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukemia. Human Molecular Genetics 1999; 8: 1741-1749.
29. Redner RL, Rush EA, Faas S et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882-886.
30. Wells RA, Catzavelos C & Kamel-Reid S. Fusion of retinoic acid receptorα to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genetics 1997; 17: 109-113.
31. Zelent A, Guidez F, Melnick A et al. Translocations of the RARα gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186-7203.
32. Kitamura K, Hoshi S, Koike M et al. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. British Journal of Haematology 2000; 108: 696-702.
33. Warrell RP, He L-Z, Ricon V et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute 1998; 90: 1621-1625.
34. Minucci S, Nervi C, Lo Coco F et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001; 20: 3110-3115.
35. van Oostveen J, Bijl J, Raaphorst F et al. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia 1999; 13: 1675-1690.
36. Owens BM & Hawley RG. HOX and non-HOX omeobox genes in leukemic hematopoiesis. Stem Cells 2002; 20: 364-379.
37. Chang CP, de Vivo I & Cleary ML. The Hox cooperativity motif of the chimeric oncoprotein E2a-Pbx1 is necessary and sufficient for oncogenesis. Molecular Cellular Biology 1997; 17: 81-88.
38. Borrow J, Shearman AM & Stanton Jr VP. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nature Genetics 1996; 12: 159-167.
39. von Lindern M, Fornerod M, Soekarman N et al. Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene. Baillière's Clinical Haematology 1992; 5: 857-879.
40. Salesse S & Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002; 21: 8547-8559.
41. Pane F, Intrieri M, Quintarelli C et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002; 21: 8652-8667.
42. Advani AS & Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leukemia Research 2002; 26: 713-720.
43. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Baillière's Clinical Haematology 2001; 14: 497-529.
44. Popescu NC & Zimonjic BB. New genetic techniques in cancer analysis. Molecular cytogenetic characterization of cancer cell alterations. Cancer Genetics and Cytogenetics 1997; 93: 10-21.
45. Sen F, Vega F & Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. Seminars in Diagnostic Pathology 2002; 19: 72-93.
46. Bayani JM & Squire JA. Applications of SKY in cancer cytogenetics. Cancer Investigation 2002; 20: 373-386.
47. Schoch C, Schnittger S, Klaus M et al. AML with 11q23/MLL abnormalities as defined by the WHO-classification: incidence, partner chromosomes, FAB-subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML. Blood 2003; (in press).
48. van Dongen BM, Macyntyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-I Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
49. van Der Velden VH, Hochhaus A, Cazzaniga G et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-1034.
50. Falini B & Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409-426.
51. Falini B, Flenghi L, Fagioli M et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 1997; 90: 4046-4053.
52. Dyck JA, Warrell Jr RP, Evans RM et al. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood 1995; 86: 862-867.
53. Villamor N, Costa D, Aymerich M et al. Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. American Journal of Clinical Pathology 2000; 114: 786-792.
54. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
55. Vardiman JW, Harris NL & Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
56. Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43-52.
57. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Annals of Oncology 1999; 10: 1419-1432.
58. Faderl S, Garcia-Manero G, Thomas DA & Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia - current concepts and future perspectives. Reviews in Clinical and Experimental Hematology 2002; 6: 142-160.
59. Lo Coco F, De Santis S, Esposito A et al. Molecular monitoring of hematologic malignancies: current and future issues. Seminars in Hematology 2002; 39: 14-17.
60. Gabert J, Beillard E, van der Velden VHJ. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer Program. Leukemia 2003 (in press).
61. Pui CH. Acute lymphoblastic leukemia in children. Current Opinion in Oncology 2000; 12: 3-12.
62. Miller WH, Levine K, DeBlasio A et al. Detection of minimal residual disease in acute promyelocytic leukaemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993; 82: 1689-1694.
63. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997; 337: 1021-1028.
64. Grimwade D & Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-1973.
65. Fukutani H, Naoe T, Ohno R et al. Prognostic significance of the RT-PCR assay of PML/RARa transcripts in acute promyelocytic leukaemia. Leukemia 1995; 9: 588-593.
66. Takatsuki H, Umemura T, Sadamura S et al. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RARa fusion mRNA: a study in patients with acute promyelocytic leukaemia following peripheral stem cell transplantation. Leukemia 1995; 9: 889-892.
67. Román J, Martín C, Torres A et al. Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukaemia. Bone Marrow Transplantation 1997; 19: 679-683.
68. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter AIDA trial. Blood 1998; 92: 784-789.
69. Bolufer P, Barragán E, Sanz MA et al. Monitoring of minimal residual disease with the combined detection of PML/RAR alpha and RAR alpha/PML rearrangements in acute promyelocytic leukemia. Medicina Clinica (Barcelona) 2000; 114: 281-285.
70. Gameiro P, Vieira S, Carrara P, Silva AL et al. The PML-RARα transcript in long-term follow-up of acute promyelocytic leukaemia patients. Haematologica 2001; 86: 577-585.
71. Jurcic JG, Nimer SD, Scheinberg DA et al. Prognostic significance of minimal residual disease detection and PML/RARα isoform type: long term follow-up in acute promyelocytic leukaemia. Blood 2001; 98: 2651-2656.
72. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukaemia. Blood 1999; 94: 2225-2229.
73. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996; 2: 561-566.
74. Kurzrock R, Kantarjian HM, Druker BJ & Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Annals of Internal Medicine 2003; 138: 819-830.
75. Kiyol H, Ohno R, Ueda R et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002; 21: 2555-2563.
76. Levis M, Allebach J, Tse KF et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.